- ASIT Biotech
- Circassia
- Mylan N.V
- Adamis Pharmaceuticals Corporation
- Merck KGaA
- Stallergenes Greer plc
- Allergy Therapeutics
- Hollisterstier Allergy
- Leti pharma
- DBV Technologies SA
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Allergy Immunotherapy Market:
-
According to a press release from Aravax Pty Ltd, Phase 2 clinical trials for PVX108, a cutting-edge immunotherapy for treating peanut allergy, started in March 2022.
Allergy immunotherapy is a treatment method for allergies that involves exposing the patient to increasing allergen dosages progressively over time. This assists the body in developing tolerance to the allergen, reducing the severity of symptoms and the risk of anaphylaxis. Allergy immunotherapy can be administered in different forms, such as subcutaneous injections, sublingual drops or tablets, and intranasal sprays. The allergy immunotherapy market is driven by numerous factors, including the increasing prevalence of allergies. With the rise in air pollution, exposure to chemicals, and changing lifestyles, allergies are becoming more common, driving the demand for effective treatments. In addition to the increasing prevalence of allergies, technological advancements are also influencing the growth of the allergy immunotherapy market. For example, developing new formulations, such as sublingual tablets and drops, has made allergy immunotherapy more convenient and less invasive for patients. There have also been advancements in the delivery methods of allergy immunotherapy, such as using autoinjectors and prefilled syringes, which have improved the ease and safety of administration. Another factor driving the growth of the allergy immunotherapy market is the increasing awareness of the benefits of this treatment method among healthcare professionals and patients. As more studies are conducted, and data is collected, the efficacy of allergy immunotherapy is becoming more widely recognized, leading to greater demand for this treatment.
Despite these positive trends, there are also various challenges facing the allergy immunotherapy market. The major challenge associated with the allergy immunotherapy market is the cost of treatment, which can be a barrier to access for some patients. Additionally, the regulatory environment for allergy immunotherapy can vary from country to country, creating challenges for manufacturers seeking to bring their products to market.